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Abstract
Background: Acute inflammatory demyelinating polyneuropathy (AIDP) is an uncommon form 
of neuropathy in HIV-infected patients that can cause pain, sensory disturbance, and motor 
weakness.
Case presentation: A 23-year-old African American male with past medical history of 
Guillain-Barre Syndrome (GBS), Lyme disease, and sexually transmitted infections including 
syphilis and chlamydia presented with acute back pain radiating to bilateral lower extremities with 
worsening right foot weakness for four days. Cerebrospinal fluid (CSF) studies including 
meningoencephalitis panel were negative as well as blood tests for Lyme disease and HIV 
antibody testing. Patient was initially treated with penicillin for positive treponemal serology but 
without improvement in lower extremity weakness. Electromyogram showed evidence of early 
demyelinating motor polyneuropathy. Four days after presentation, repeat HIV antibody testing 
returned positive. Recurrent AIDP in this case was suspected to be secondary to acute HIV 
infection, and highly active antiretroviral therapy (HAART) was administered along with 
intravenous immunoglobulin (IVIG). Muscle strength improved with therapy and patient was 
expected to have continued improvement with intensive rehabilitation after discharge.
Conclusion: Acute inflammatory demyelinating polyneuropathy (AIDP) tends to present early 
in course of HIV infection. Therefore, HIV testing should be obtained in individuals presenting 
with new neurological deficits. Our patient received HAART therapy, in addition to the traditional 
modalities to manage AIDP, which led to a substantial recovery of his sensorimotor function.
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The advent of highly active antiretroviral therapy (HAART) has resulted in massive 
improvement in the quality of life of people infected with human immunodeficiency virus 
(HIV) [1]. Despite this progress, about seventy percent of HIV patients develop neurological 
complications that originate in the central or peripheral nervous system as a primary or 
secondary disorders [1,2]. Primary disorders occur from the direct effects of the virus on the 
immune system leading to HIV-associated neurocognitive disorders (HAND), HIV-
associated vascular myelopathy, and a number of neuropathies [2,3,4]. In turn, secondary 
disorders result from marked immunosuppression and include primary central nervous 
system lymphoma and opportunistic infections [4,5].
Peripheral nervous system disorders in HIV-infected patients can cause pain, sensory 
disturbance, and motor weakness [2,3,6]. The peripheral disorders are categorized into distal 
symmetric polyneuropathy, inflammatory demyelinating polyneuropathy (IDP), 
mononeuropathy/mononeuropathy-multiplex, and radiculopathies [6,7]. Of the above, 
inflammatory demyelinating polyneuropathy is an uncommon form of neuropathy in HIV-
infected patients with a handful of data available [6,8]. Along with the rarity of the 
association between HIV and GBS, we described resolution of inflammatory 
polyneuropathy upon initiation of HAART. We present the case of a young patient who had 
suffered GBS three years prior and developed new right lower extremity weakness. Work-up 
revealed HIV seroconversion, negative Epstein Barr Virus in CSF and early demyelinating 
motor polyneuropathy on electromyogram leading to the diagnosis of inflammatory 
demyelinating polyneuropathy in the setting of newly diagnosed HIV.
2. Case Presentation
A 23-year-old male presented with lumbar back pain radiating to the lower extremities and 
worsening right foot weakness that began four days before. Patient also reported 
unintentional fifteen-pound weight loss over the past four months. Past medical history 
included treatment for sexually transmitted infections (syphilis and chlamydia) and three 
years prior, and episode of Guillan-Barre syndrome (GBS), presumed to be secondary to 
Lyme disease from which he had recovered completely. Social history was significant for 
high-risk sexual behavior and a long-term HIV-positive partner with undetectable viral load. 
Neurological exam revealed normal tone throughout but reduced strength (3/5) in the right 
lower extremity with reduced sensation distal to the right patellofemoral joint. The right 
patellar reflex was absent with 2+ reflexes elsewhere. The rest of the clinical examination 
was normal.
On examination, temperature was 36.7C, pulse of 43 beats per minute, blood pressure 
112/73 mmHg, respiratory rate 17 breaths per minute, and oxygen saturation was 100% on 
ambient air. Initial blood tests showed: white blood cell count 3.1×109 and platelet count 
147,000. CSF examination was unremarkable: no mononuclear cells or polymorphonuclear 
leukocytes, protein level of 32 mg/dL, and a glucose level of 53 mg/dL. Further blood tests 
revealed negative immunoglobulins M/G for Lyme disease, negative HIV antibody testing, 
positive IgG for Epstein Barr Virus, and positive treponemal serology with a rapid plasma 
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reagin (RPR) of 1:8. An MRI of the lumbar spine was remarkable for abnormal 
enhancement of the cauda equina roots (Figure 1). MRI of the head, cardiac MRI, and 
transthoracic echocardiogram were all within normal limits. Cardiology was consulted for 
bradycardia and recommended outpatient follow-up in the background of an otherwise 
normal EKG with bradycardia and normal ejection fraction on echocardiogram.
The suspected diagnosis was neurosyphilis and CSF treponemal antibodies were ordered. 
The patient received intravenous penicillin G with frequent neurological examinations 
however, the right lower extremity sensory deficit did not show any improvement. 
Electromyogram revealed an early demyelinating predominantly motor polyneuropathy. 
Patient had been successfully treated for syphilis two years ago with RPR titers that had 
reduced from 1:128 to 1:2. CSF studies including polymerase chain reaction analyses, and 
antibody testing were negative for Lyme disease, syphilis, herpes simplex virus, herpes 
zoster virus, Epstein-bar virus, and cytomegalovirus.
Screening for other blood-borne viruses, opportunistic infections, and MRI of the brain were 
all negative. In view of the established risk factors and new findings, a repeat HIV test was 
done on hospital day 4 and resulted positive. The HIV viral load was >500,000 copies/ml 
and the CD4 count was 574 cells/mm3. There was a high clinical suspicion for inflammatory 
demyelinating polyneuropathy secondary to an acute HIV infection and patient was started 
on highly active antiretroviral therapy (HAART) along with intravenous immunoglobulin 
(IVIG). His strength improved (4/5) with therapy and physical therapy recommended acute 
rehabilitation. On hospital day 12, patient was discharged with close follow-up.
3. Discussion
Acute inflammatory demyelinating polyneuropathy (AIDP) is rarely reported in HIV 
patients but it is one of the most common variants of Guillain Barre Syndrome [9,10,11]. 
When it occurs, AIDP would be expected early in course of HIV infection or seroconversion 
[9,13,14]. Patients often present asymptomatically, and it is important to consider HIV 
testing in otherwise healthy individuals with newfound neurological presentation. The 
pathogenesis is an HIV triggered inflammatory or autoimmune process that targets the 
myelin sheath, causing demyelination. Antibodies against peripheral myelin glycolipids 
have been identified in HIV patients presenting with AIDP [15]. The presentation is a rapid, 
symmetric, ascending motor weakness with generalized areflexia and sparing of sensation 
[12,13]. Our patient’s presentation is atypical of AIDP: presenting acutely with an 
asymmetric ascending motor weakness limited to the right lower extremity and in addition, 
this patient had GBS in the past, prior to having the diagnosis of HIV.
Recurrent GBS has been reported in the literature with an incidence of three to six percent 
[23]. Unlike chronic inflammatory demyelinating neuropathy (CIDP), patients with 
recurrent GBS are generally under thirty with shorter intervals between recurrences and 
accumulating neurologic deficits with each recurrence [24]. Recurrent GBS in HIV patients 
has not been well studied but multiple cases have reported GBS initially with seroconversion 
and later recurrences with immune reconstitution following HAART therapy [24,25]. Our 
patient had a previous history of GBS three years before, an initial negative HIV test and 
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neurological deficits compatible with recurrent GBS; repeat HIV test revealed 
seroconversion.
The diagnosis of AIDP is based on clinical features, CSF analysis, and electrophysiological 
studies [7,17,18]. CSF analysis typically shows an elevated protein and mild lymphocytic 
pleocytosis. Elevated protein has been reported in 80% of all cases while CSF white cells are 
not seen in HIV seronegative patients [7,19]. Our patient had a normal CSF with a protein 
and glucose levels.
AIDP following HIV seroconversion has been shown to present with clinical features that 
are unlike characteristic findings. In existing literature, one patient presented with 
quadriparesis, while two other patients presented with progressive upper or lower extremity 
weakness along with dyspnea, dysarthria, and facial palsy [8,13,14]. Patients can also have 
symptoms of autonomic and respiratory dysfunction [8,16]. Although our patient’s 
symptoms were isolated to the right lower extremity, he presented with new onset 
bradycardia, possibly secondary to autonomic dysfunction.
Treatment of AIDP is directed at the antibodies targeting the myelin sheath. Generally, 
AIDP in HIV patients is treated with IVIG 400 mg/kg/day for five days [11,16,20]. Plasma 
exchange can also be used in patients with contraindications or lack of response to therapy. 
Although less common, prednisone 1 mg/kg/day can be used. While IVIG and plasma 
transfusion target antibodies, there has been increasing research about the role of HAART 
therapy for AIDP [1,4,16,21]. It has been reported that early introduction of HAART can 
improve disease course and prove beneficial [11,14,22]. Our patient was treated with IVIG 
for five days along with initiation of HAART therapy.
4. Conclusion
AIDP is a GBS variant and rarely reported among HIV patients. AIDP have a wide spectrum 
of clinical presentations that range from asymptomatic to rapidly ascending motor weakness 
with generalized areflexia and signs of autonomic dysfunction. Our patient with recurrent 
AIDP who presented with bradycardia and an asymmetric ascending motor weakness of the 
RLE. This time, the patient presented in the setting of acute HIV seroconversion and 
symptoms improved with the initiation of appropriate therapy for HIV and AIDP. In a young 
person with acute neurologic symptoms, not all findings may be clear and a unifying 
diagnosis requires careful analysis. The diagnosis of AIDP in our patient was based on a 
combination of clinical features, serologic testing, and electrophysiological studies. It is 
important to consider HIV testing in high-risk individuals with newly found neurological 
presentation. Traditional treatment for AIDP involves IVIG however, we observed a 
significant clinical improvement of AIDP upon the initiation of HAART therapy, suggesting 
that targeted therapy for HIV infection addressed the underlying pathogenesis of AIDP in 
this patient. Further studies are needed to confirm our hypothesis.
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MRI of the lumbar spine demonstrating abnormal enhancement of the cauda equina roots
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